Metagenomi Technologies, LLC
Metagenomi Technologies, LLC is listed today as Metagenomi Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
5 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2022 | $96 M | No. 5 | $50 to $250 million | equity | SEC | |
| Jan 2022 | $175 M | No. 4 | $50 to $250 million | equity | SEC | |
| Mar 2021 | $10 M | No. 3 | $10 to $50 million | equity | SEC | |
| Nov 2020 | $38 M | No. 2 | $10 to $50 million | equity | SEC | |
| Aug 2019 | $26 M | No. 1 | $10 to $50 million | equity, debt | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Metagenomi Technologies, LLC chose not to state its revenue in its newest notice of a funding round (Jan 2023).
SEC Form D · Jan 2023
The industry group it chose in its notices: Other Technology.
SEC Form D · Jan 2023
That is all the official record says: Metagenomi Technologies, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Metagenomi Technologies, LLC are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bayer Healthcare LLC | Other | not stated | not stated | Held Series A-1, A-4, B and B-1 preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Bayer US Holding LP | Fund or asset manager | not stated | not stated | Held Series A-1, A-4, B and B-1 preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Bayer World Investments B.V. | Fund or asset manager | not stated | not stated | Held Series A-1, A-4, B and B-1 preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series B and B-1 preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Sebastian Bernales | Person | not stated | not stated | Held Series A-2, A-3 and A-4 preferred stock, director (Form 3, 2024) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 29 investors.
Largest shareholders today
Institutions holding Metagenomi Therapeutics, Inc. shares, as of Sep 30, 2026.
- Vanguard Capital Management LLC$1 M2.85%
- Renaissance Technologies LLC$1 M1.65%
- Catalio Capital Management, LP$1 M1.40%
- Two Sigma Investments, LP$1 M1.33%
- Peapod Lane Capital LLC$1 M1.30%
- Wells Fargo & Company/mn$0 M1.12%
- Bridgeway Capital Management, LLC$0 M0.99%
- Almitas Capital LLC$0 M0.75%
- Geode Capital Management, LLC$0 M0.73%
- BlackRock, Inc.$0 M0.67%
- Vanguard Fiduciary Trust Co$0 M0.45%
- Man Group plc$0 M0.38%
- State Street Corp$0 M0.32%
- Resolute Advisors LLC$0 M0.24%
- Millennium Management LLC$0 M0.20%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brian C. Thomas | Executive officer | Jan 2023 |
| Brian Thomas | Manager | Feb 2022 |
| Brian C. Thomas | Director | Jan 2023 |
| Juergen C. Eckhardt | Director | Jan 2023 |
| Risa C. Stack | Director | Jan 2023 |
| Santhosh C. Palani | Director | Jan 2023 |
| Sebastian C. Bernales | Director | Jan 2023 |
| Willard C. Dere | Director | Jan 2023 |
| Brian Thomas | Manager | Feb 2022 |
| Juergen Eckhardt | Manager | Feb 2022 |
| Risa Stack | Manager | Feb 2022 |
| Santosh Palani | Manager | Feb 2022 |
| Sebastian Bernales | Manager | Feb 2022 |
| Willard Dere | Manager | Feb 2022 |
| Andrew Farquharson | Director | Mar 2021 |
| Andrew Levin | Director | Mar 2021 |
| Jak Knowles | Director | Aug 2019 |
| Brian Thomas | Promoter | Mar 2021 |
Went public since 2024. Its SEC number is that of a company listed on a stock exchange.